T he TAXUS Liberte -Post Approval Study (TL-PAS) is a prospective, multicenter, open-label study developed to review clinical performance of the TAXUS Liberté paclitaxel-eluting coronary stent (PES) in routine clinical practice in the United States. The TAXUS Liberté PES is a secondgeneration PES produced by Boston Scientific Corporation (Marlborough, MA), designed to ease stent placement and enhance drug delivery through use of a lower mass 316 L stainless steel stent (97 μm thickness) with a novel strut configuration; the polymer compound and paclitaxel formulation were unchanged from those used in the first generation TAXUS Express 2 PES. 1,2 The principal objective of TL-PAS was to fulfill United States (US) Food and Drug Administration (FDA) requirements for surveillance of drug-eluting stent (DES) performance after commercial release. As TL-PAS was being developed, the Dual Anti-Platelet Therapy (DAPT) Study was organized. 3 The DAPT Study is a multi-center, randomized, double-blind, placebo-controlled trial comparing dual antiplatelet therapy for 12 versus 30 months after DES placement. FDA had requested that US stent manufacturers Background-The TAXUS Liberte -Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. Methods and Results-Outcomes for 2191 TL-PAS patients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P<0.001).
provide support for this study, and that approved stent types and P2Y 12 receptor inhibitor therapies be included. Boston Scientific Corporation collaborated with Daiichi Sankyo (Parsippany, NJ), Eli Lilly (Indianapolis, IN), and the DAPT Study investigators to enroll patients from TL-PAS into the DAPT Study. Suitable TL-PAS patients who were free of disqualifying events after 12 months of open-label prasugrel plus aspirin were eligible for randomization to continued treatment with blinded prasugrel or placebo, plus aspirin, for an additional 18 months, after which study drugs were stopped and aspirin was continued for at least an additional 3 months. Serious ischemic events and bleeding were assessed.
TL-PAS patients represented the largest portion of PES patients, and the largest cohort receiving prasugrel, enrolled into the DAPT Study. Although the results of the overall study that included several different drug-eluting stents and both clopidogrel and prasugrel are reported separately, 4 understanding outcomes within this unique subgroup may provide important additional insights into the impact of long and short duration of prasugrel therapy after placement of a PES. 5
Methods

Study Design and Methods
The TL-PAS design and primary end point of cardiovascular death or myocardial infarction (MI) 12 months after stent placement have been described previously. 6, 7 Briefly, TL-PAS included 4199 patients and was designed to assess the performance of the TAXUS Liberté PES relative to the first generation TAXUS Express 2 PES in routine clinical practice. As such, recruitment was broad, permitting inclusion of patients with a variety of clinical indications, including elective stable patients and patients with acute coronary syndromes (ACS). 6 The DAPT Study design and end points have also been described previously. 1 The DAPT Study is an international, multicenter, randomized, double-blind, placebo-controlled trial that enrolled 22 866 subjects treated with various DES and aspirin plus either clopidogrel or prasugrel, with the objective of determining whether dual antiplatelet therapy beyond 12 months is associated with a reduction in major adverse cardiovascular and cerebrovascular events (MACCE) or stent thrombosis (ST), and to assess the impact of prolonged antiplatelet therapy on major bleeding. TL-PAS participants meeting inclusion requirements were eligible for participation in the DAPT Study; TL-PAS patients randomized in the DAPT Study are the focus of this article.
Enrolled TL-PAS patients received open-label prasugrel plus aspirin for 12 months after stent placement; enrollment was not restricted to patients presenting with ACS (ie, those with an approved indication for prasugrel). Prasugrel dosing and exclusion criteria used in this study have been described. 6 Patients were excluded if they had a history of previous cerebrovascular event or active bleeding disorder. A reduced prasugrel maintenance 5-mg dose was recommended for patients with body mass <60 kg and those ≥75 years of age.
Patients were eligible for DAPT Study randomization 12 months after the index procedure if they (1) were alive and free of coronary artery bypass grafting surgery, stroke, ST, or major bleeding event at any time after stent placement; (2) had not sustained MI or required percutaneous coronary intervention (PCI) beyond 6 weeks after their index procedure; (3) had been compliant with antiplatelet medications. Qualified subjects continued open-label aspirin and were 2191 patients were randomized. Patients free of death, coronary artery bypass graft, stroke, stent thrombosis, or major bleeding event at any time after stent placement, and free of myocardial infarction and percutaneous coronary intervention beyond 6 weeks after initial stent placement, and who had been compliant with antiplatelet therapy, were eligible for DAPT Study randomization. ASA indicates aspirin. 
End Points
In this exploratory analysis, the coprimary end points of the DAPT Study were analyzed within the TL-PAS subgroup of randomized patients; these end points were (1) MACCE, defined as the composite of all-cause death, MI, or stroke, and (2) ST, occurring between 12 and 30 months after the index procedure. 3 
Statistics
No power calculations were performed for clinical end point comparisons between treatment groups in this analysis because these data represent a patient subset of the DAPT Study, which had powered end points. However, it was prespecified in the TL-PAS protocol and statistical analysis plan that DAPT Study clinical outcome data in TL-PAS would be examined after unblinding for exploratory purposes.
Because populations were defined through randomization, group comparisons were not performed for baseline characteristics, as recommended by the Consolidated Standards of Reporting Trials (CONSORT) guidelines. 10 For end points, discrete variables were reported as counts and percentages, and differences were estimated by χ 2 or Fisher exact tests. Cumulative event rates were estimated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards regression model for time-to-event data was used to estimate the hazard ratio (HR) and its confidence interval (CI). The HR is an estimate of the ratio of the hazard rate in the 30-month prasugrel treatment group compared with the 12-month prasugrel treatment group. 11 The TL-PAS DMC monitored adverse clinical events and were to notify TL-PAS sponsors in the event of a concerning safety signal. Data for any patient whose treatment was unblinded for any reason was censored at the time of unblinding.
Results
TL-PAS enrolled 4199 patients at 82 investigative sites in the US from December 2009 to January 2012; details have been described previously. 7 Twenty-six patients (including 11 patients participating in the DAPT Study) were excluded from analysis because of significant concerns over protocol compliance at 1 investigative site; inclusion or exclusion of these patients did not alter results meaningfully (data on file), and data from this site were included in the primary DAPT Study analysis. Patient flow is displayed in Figure 1 . Only patients enrolled into TL-PAS before July 1, 2011 (n=3878) could participate in the DAPT Study. Of these patients, 384 did not complete the 12-month follow-up visit; an additional 1303 were not randomized (688 because they met ≥1 DAPT Study exclusion criteria, 613 because of physician or patient choice, 2 for unknown reasons). The remaining 2191 patients were randomized 12 months after the index procedure to receive placebo (n=1093, 12-month prasugrel treatment group) or blinded prasugrel (n=1098, *Emergency procedure is defined as percutaneous coronary intervention performed for ischemic symptoms occurring at rest, lasting ≥10 min, occurring within 72 h before index procedure, and either ST-segment deviation ≥1 mm or elevated levels of a cardiac biomarker of necrosis (CK-MB or troponin T or I greater than the upper limit of normal; if CK-MB or troponin is not available, total CK >2 times upper limit of normal). Denominators are procedure based.
†Denominators are lesion based. ‡Inclusive of staged procedures. §Denominators are stent based.
30-month treatment groups, respectively ( Figure I Cumulative occurrences of the coprimary end point MACCE and its components (all-cause death, stroke, or ARC MI) through 630 days after randomization (33 months after index procedure) are shown in Figure 2 ; all primary and secondary analysis events and bleeding rates are displayed for both groups at the 90-, 540-, and 630-day time points in Table 3 . More MACCE were observed shortly after randomization in the 12-month treatment group, as prasugrel therapy was replaced with placebo (time 0 on the curve), compared with the 30-month treatment group; the difference in MACCE was significant at 90 days after randomization (0.7% versus 2.4%; HR, 0.303; 95% CI, 0.137-0.670; P=0.002; Figure 2A ). The time-to-event curves continued to diverge between 90 days and 540 days after randomization (30 months after stent placement); the difference between the placebo and continued prasugrel groups was significant at this time point (HR, 0.407; 95% CI, 0.281-0.589; P<0.001), indicating benefit with prolonged prasugrel and aspirin therapy for this end point. An upward inflection in the time-to-event curve for MACCE between 30 and 33 months was then observed in the 30-month treatment group, because prasugrel was withdrawn after 30 months. This pattern was similar to the increase in MACCE observed in the 12-month treatment group as prasugrel was withdrawn after 12 months. Despite this, MACCE remained significantly lower in the continued prasugrel group at 33 months (630 days after randomization; P<0.001; HR, 0.592; 95% CI, 0.431-0.812).
Rates of all-cause death ( Figure 2B ) and stroke ( Figure 2C ) were similar throughout follow-up, whereas rates of MI were higher in the 12-month prasugrel group ( Figure 2D) , which largely accounted for the difference in MACCE observed between treatment groups. Specifically, an early separation in MI rates between the 2 treatment cohorts was evident within 90 days of randomization, continued divergence of curves was observed through 540 days, and an increase in MI rates was seen in the prolonged prasugrel treatment group between 540 and 630 days, as prasugrel was stopped.
In response to the increases in MI after withdrawal of prasugrel therapy after both 12 and 30 months of treatment, the TL-PAS DMC recommended in mid-2013 that randomized treatment be unblinded for TL-PAS patients who had not yet completed 30-month follow-up, to allow discussion of continuing open-label prasugrel beyond 30 months for those randomized to active drug. Treatment was unblinded at the 30-month time point for 12 patients (1.1%) in the 12-month prasugrel group and 15 patients (1.37%) in the 30-month prasugrel group as a result of the TL-PAS DMC recommendation.
Rates of the coprimary end point of ARC definite or probable ST are shown in Figure 3A . The ST rate was significantly was associated with important reductions in MI related to ST ( Figure 3B ) as well as spontaneous MI not related to ST ( Figure 3C ). TVR related to MI followed a similar pattern, with significantly lower TVR rates in the extended prasugrel group at 90, 540, and 630 days after randomization; TVR not related to MI displayed no significant differences between cohorts at any time point ( Figure II in the online-only Data Supplement).
The safety end point of GUSTO moderate or severe bleeding was numerically increased in the patients continuing prasugrel to 30 months, although the difference was not statistically significant ( Figure 4A; 2.4% versus 1.7%; HR, 1.438; P=0.234) . The majority of bleeding events in both groups were of moderate severity; importantly, the frequency of severe bleeding events was not different between groups ( Figure 4B ; 0.3% versus 0.5%; HR, 0.549; P=0.471). Intra-cranial hemorrhage events (0.3% versus 0.4%; HR, 0.742; P=0.695) and fatal bleeding events (0.0% versus 0.2%; P=0.155) occurred with similar low frequencies after 30 and 12 months therapy, respectively.
Discussion
Concerns over late and very late stent thrombosis led to a revision of PCI practice guidelines which have, since 2007, recommended dual antiplatelet therapy for at least 12 months after DES placement in patients with low bleeding risk. 12 This recommendation is general, not specific to any particular stent or drug. No adequately powered comparative trials have determined whether therapy beyond 12 months provides additional clinical benefit that counterbalances potential increased bleeding. To address these needs, the Dual Antiplatelet Therapy Study (DAPT) evaluated the risks and benefits of prolonging dual antiplatelet therapy with either clopidogrel or prasugrel administered for 30 months compared with 12 months after PCI in patients receiving a variety of DES and bare metal stents. Risks with PES have been of particular concern after early reports of possible increased thrombosis risk. 13 Among TL-PAS patients receiving TAXUS Liberté PES and enrolled into the DAPT Study, continuation of prasugrel plus aspirin to 30 months was associated with a 60% reduction in MACCE (HR, 0.407), largely explained by a 75% reduction in ARC-defined MI (HR, 0.255); >90% reduction in ARCdefined definite or probable ST (HR, 0.063) was also observed. Importantly, prolonged prasugrel plus aspirin reduced MI occurring as a consequence of ST and MI occurring spontaneously. However, cessation of prasugrel was associated with an early increase in ischemic events, primarily MI, whether the drug was stopped after 12 or 30 months, implicating loss of protective drug effect as causal at both time points. Because these findings indicated persisting risk of serious ischemic events beyond 30 months the TL-PAS DMC recommended unblinding of DAPT Study treatment assignment to permit discussion of continuing prasugrel for remaining TL-PAS patients randomized to active prasugrel through 30 months.
These observations are in contrast to other recent studies that reported relative safety with shorter periods of dual antiplatelet therapy. Some of these trials [14] [15] [16] [17] [18] [19] [20] reported no apparent reduction in ischemic events but increased bleeding with prolonged thienopyridine therapy, which prompted a revision of European Society of Cardiology practice guidelines in 2014 to recommend just 6 months dual antiplatelet therapy after DES. 21 However, all of these studies were conducted outside the US and tested only clopidogrel therapy, most randomized patients at the time of the index procedure, most were not placebo-controlled, few included study of PES, and most were interested in testing the safety of dual antiplatelet therapy for <12 months. With 1 exception, none were adequately powered for clinical end points. The Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE) study 19 from Korea randomized a large number of patients who were free of adverse events after 12 months to continued clopidogrel plus aspirin or aspirin alone; this study found no important difference in adverse ischemic events or major bleeding using Thrombolysis In Myocardial Infarction (TIMI) definitions. The final design of DES-LATE was adequately powered for the end points of interest but was not placebo controlled. PROlonging Dual antiplatelet treatment after Grading stentinduced Intimal hyperplasia studY (PRODIGY) compared 6 and 24 months unblinded therapy with clopidogrel plus aspirin in bare metal and several first-and second-generation DES. 18 PRODIGY was a broad study of stent performance characteristics and was not powered to assess clinical outcomes. Still, PRODIGY reported similar ischemic event rates with short and long duration clopidogrel therapy, and observed that stent type was an important determinant of late events, with PEStreated patients experiencing higher ischemic event rates than other DES recipients, especially between 12 and 24 months. 22 No trial data are available regarding prasugrel use for more or less than 12 months after DES placement other than from the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel (TRITON TIMI) 38 study, which found important ischemic event reductions with prasugrel rather than clopidogrel for 15 months after placement of first generation DES in the setting of ACS. 23 Thus, although available studies have important limitations, current data suggest that type of coronary stents placed, antiplatelet drugs used, and population treated are important determinants of clinical outcomes, in addition to duration of antiplatelet drug treatment.
Relatively few clinical studies exist to inform clinical decisions regarding prasugrel use beyond the first 12 months after coronary stent placement. The A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pretreatment At the time of diagnosis in patients with non-ST-elevation MI (ACCOAST) study 24 found no reduction in ischemic events compared to placebo when a 30-mg loading dose of prasugrel was given before angiography in ACS patients, but did observe increased major bleeding at 7 days follow-up compared with patients receiving the approved 60-mg loading dose given at the time of intervention. In the TaRgeted Platelet Inhibition to CLarify the Optimal StrateGy to MedicallY Manage ACS (TRILOGY ACS) study, medically-managed patients with non-ST-segmentelevation ACS were treated with prasugrel or clopidogrel on a background of aspirin for up to 30 months. 25 In a prespecified analysis, the subgroup of patients in TRILOGY ACS who underwent coronary angiography before randomization 26 had a greater reduction in ischemic events, including both cardiovascular death and MI, through 30 months without an increase in major bleeding with long-term prasugrel compared with clopidogrel, even though few patients underwent coronary revascularization. Thus, outcomes in both TRITON TIMI 38 and the angiographic subgroup of TRILOGY ACS suggest that more potent inhibition of platelet activation during maintenance dosing with prasugrel compared with clopidogrel confers benefit in patients with angiographically confirmed coronary artery disease. The findings in our study support this conclusion and, additionally, indicate benefit with continuing prasugrel beyond 12 months in patients undergoing coronary intervention with TAXUS Liberté PES.
We observed significant residual risk of ischemic events beyond 12 months after TAXUS Liberté PES placement, and found that loss of protection when prasugrel is withdrawn, even after 30 months, was associated with increased ischemic events. Interest in suppressing residual risk, particularly after an ACS event, underlay other secondary prevention studies involving antithrombin (eg, TRA-2P) 27 and antiplatelet (eg, PEGASUS) 28 therapies. Although we observed that prolonged prasugrel led to important ST reductions, most MI observed were not related to ST, and a reduction in spontaneous MI with continued prasugrel and aspirin therapy was also observed. Additionally, the rise in MI events observed after prasugrel cessation after both 12 and 30 months treatment reflected primarily spontaneous events. Thus, suppression of MI unrelated to the stent placed accounted for an important portion of the benefit of prolonged prasugrel therapy.
Safety concerns over late bleeding events have driven interest in shorter therapeutic periods. We found that prolonged prasugrel was associated with an ≈40% increase in the relative risk of significant bleeding that did not reach statistical significance. The absolute difference of 0.8% in GUSTO moderate or severe bleeding observed between 12 and 30 months prasugrel therapy was largely a reflection of increased moderate bleeding events; we observed no signal of increased severe bleeding events, including fatal bleeding or intracranial hemorrhage, with therapy prolonged to 30 months. It should be noted, however, that this study cohort had demonstrated ability to tolerate 12 months prasugrel and aspirin before randomization.
Limitations
This analysis of TAXUS Liberté patients from TL-PAS was not powered for the end points studied in the DAPT Study. In particular, the power to assess rare events, including stent thrombosis and death, is limited. Patients were excluded from TL-PAS if they had a history of previous cerebrovascular or active bleeding events. Subjects with very low body mass or advanced age were recommended to receive a lower maintenance dose of prasugrel, and may have been underrepresented in the study. All randomized subjects had demonstrated the ability to tolerate 12 months prasugrel plus aspirin without bleeding. Our observations cannot be generalized to other stents or antiplatelet agents; unique aspects of the TAXUS Liberté PES or prasugrel may account for the observations.
Conclusions
Compared with aspirin monotherapy after 12 months, continuing dual antiplatelet therapy with prasugrel and aspirin for 30 months was associated with lower rates of MACCE, driven largely by fewer spontaneous and ST-related MI, among patients treated with TAXUS Liberté PES. Lower rates of ST were also observed with prolonged prasugrel, with no apparent increase in severe bleeding compared with aspirin alone. Importantly, a significant rise in MI, mostly unrelated to ST, was observed after discontinuation of prasugrel at 12 or 30 months, suggesting a loss of protective effect with prasugrel. We conclude that prolonged platelet inhibition with prasugrel and aspirin suppresses serious ischemic events when therapy is continued to 30 months after TAXUS Liberté PES placement. We also conclude that risk of serious ischemic events, both related and unrelated to stent placement, persists beyond 30 months. Although these findings suggest that prasugrel and aspirin should be continued for >30 months after placement of TAXUS Liberté PES, the optimal length of therapy remains uncertain. These observations may be driven by characteristics of this particular DES, this particular drug combination, the population under study, or a combination of these factors. The primary analysis of the overall randomized DAPT Study, which encompasses several approved stent types and antiplatelet drug regimens, will be helpful in understanding these observations.
